Medicine and Dentistry
Adverse Effect
10%
Alkaline Phosphatase
17%
Antiinfective Agent
9%
Bacterial Infection
13%
Base
9%
Birth Weight
10%
Bloodstream Infection
12%
Brain Injury
26%
Caffeine Citrate
10%
Chorioamnionitis
18%
Chronic Lung Disease
12%
Coagulase Negative Staphylococcus
9%
Cohort Analysis
35%
Diagnosis
9%
Gene Linkage
17%
Gestational Age
20%
Gut
8%
Health Service
12%
High Risk Infant
11%
Histopathology
9%
Human Milk
17%
Human Respiratory Syncytial Virus
17%
Immunoprophylaxis
9%
Infection
41%
Innate Immunity
8%
Intravenous Drug Administration
10%
Lactoferrin
11%
Necrotizing Enterocolitis
13%
Neonatal Intensive Care Unit
43%
Neonatal Sepsis
88%
Neonates
9%
Newborn Intensive Care
26%
Palivizumab
26%
Parenteral Drug Administration
19%
Pathogen
10%
Pentoxifylline
12%
Peptides and Proteins
8%
Pregnancy
22%
Prematurity
38%
Probiotics
13%
Randomized Clinical Trial
18%
Randomized Controlled Trial
14%
Respiratory Tract Infection
10%
Retinopathy of Prematurity
11%
Retrospective Cohort Study
15%
Sepsis
100%
Sildenafil
17%
Staphylococcus Epidermidis
14%
Systematic Review
20%
Vancomycin
9%
Immunology and Microbiology
Agonist
11%
Alkaline Phosphatase Blood Level
8%
Antibodies
8%
Bifidobacterium Breve
9%
Blood Plasma
41%
Chorioamnionitis
39%
Coagulase Negative Staphylococcus
17%
Cytokine
27%
Cytokine Response
22%
Enterocolitis
10%
Escherichia coli
12%
Host Immune Response
8%
Human Respiratory Syncytial Virus
17%
Immaturity
7%
Immune Response
20%
Immunity
19%
Immunoassay
12%
Immunosuppression
8%
Infectious Agent
60%
Inflammation Response
9%
Inflammatory Cytokine
12%
Innate Immune System
20%
Interleukin 10
13%
Interleukin 6
15%
Interleukin-1
13%
Leukocyte
16%
Leukocyte Count
6%
Lysozyme
6%
Microbiome
6%
Mouse Model
8%
Multi-Omics
8%
Neutrophil
12%
Newborn Period
8%
Palivizumab
26%
Pentoxifylline
20%
Peptides
8%
Perinatal Period
6%
Phagocytosis
17%
Pregnancy
13%
Probiotic
17%
Proinflammatory Cytokine
6%
Proteomics
8%
Respiratory Syncytial Virus
8%
RNA Sequencing
6%
Sampling
8%
Skin Microbiome
17%
Staphylococcus Epidermidis
63%
Toll-Like Receptor
8%
Transcriptome
13%
Tumor Necrosis Factor
10%
Pharmacology, Toxicology and Pharmaceutical Science
2,5-Dimethoxy-4-iodoamphetamine
8%
Alkaline Phosphatase
17%
Bacterial Infection
12%
Base
9%
Bloodstream Infection
5%
Brain Injury
8%
Caffeine Citrate
10%
Chorioamnionitis
20%
Chronic Lung Disease
5%
Clinical Trial
9%
Coagulase Negative Staphylococcus
8%
Coconut Oil
26%
Cohort Study
20%
Congenital Malformation
8%
Critical Illness
8%
Hospital Infection
5%
Human Respiratory Syncytial Virus
9%
Hypoxic Ischemic Encephalopathy
8%
Infection
20%
Inflammation
10%
Lactobacillus plantarum
8%
Lactoferrin
8%
Lipid Emulsion
8%
Microbiome
8%
Microflora
8%
Mouse Model
8%
Necrotizing Enterocolitis
19%
Neuroprotective Agent
5%
Palivizumab
17%
Pentoxifylline
55%
Pharmacokinetics
17%
Placebo
8%
Prematurity
24%
Randomized Clinical Trial
5%
Randomized Controlled Trial
10%
Respiratory Tract Infection
9%
Secretory Phospholipase A2
8%
Sepsis
76%
Sildenafil
8%
Staphylococcus Epidermidis
13%
Vancomycin
9%